SHAREHOLDER ALERT: Investigation of Reata Pharmaceuticals, Inc. Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - December 6, 2021) - Holzer & Holzer, LLC is investigating whether Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) complied with federal securities laws. On December 6, 2021, the U.S. Food and Drug Administration ("FDA") released briefing documents ahead of an Advisory Committee meeting regarding CARDINAL, a phase 3 study conducted in support of the New Drug Application for bardoxolone. In the briefing documents, the FDA indicated that the "loss of statistical significance based on a change in a single factor in the analytic model raises concerns regarding the robustness of the study's findings." On this news the Company's stock dropped.

If you purchased Reata stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106832